Liraglutide vs MGF (Mechano Growth Factor)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Liraglutide
Liraglutide is a GLP-1 receptor agonist FDA-approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first daily GLP-1 agonists and paved the way for newer weekly options like semaglutide.
Full details →MGF (Mechano Growth Factor)
MGF (Mechano Growth Factor) is a splice variant of IGF-1 that is produced locally in muscle tissue in response to mechanical stress. The non-PEGylated form has a very short half-life.
Full details →Side-by-Side Comparison
| Aspect | Liraglutide | MGF (Mechano Growth Factor) |
|---|---|---|
| Mechanism | Binds to and activates GLP-1 receptors, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system effects. | Activates muscle satellite cells (stem cells) and promotes their proliferation without differentiation, priming them for fusion with existing muscle fibers during repair and growth. |
| Typical Dosage | Saxenda (weight loss): Start 0.6mg daily, increase weekly by 0.6mg to maintenance dose of 3mg daily. Victoza (diabetes): 0.6mg to 1.8mg daily. | Due to extremely short half-life (minutes), typical protocols use 100-200mcg injected directly into target muscles immediately post-workout. |
| Administration | Subcutaneous injection once daily at any time, independent of meals. Rotate injection sites. Can be used with oral diabetes medications. | Intramuscular injection into trained muscles within minutes of workout completion. Must be used immediately after reconstitution due to instability. |
| Side Effects | Nausea, vomiting, diarrhea, constipation, headache, decreased appetite. GI effects typically diminish over time with continued use. | Injection site soreness, potential hypoglycemia, localized swelling. Short half-life limits systemic effects. |
| Best For |